Shannon, Ireland. August 11th. Biomimetic Innovations Ltd, an affiliate of PBC
Biomed – an Irish medical device company specialising in biomimetic materials,
today announced the successful First-in-Human application of OsStic™ Injectable
Synthetic Bone Void Filler. The procedure was performed last Friday 7th August by
clinicians at University of Leeds and Leeds Teaching Hospitals NHS Trust, supported
by NIHR Clinical Research Facility: Leeds.
The first procedure involved reconstruction of a knee joint – a lateral tibial plateau
fracture (split depression injury). Professor Giannoudis confirmed that the procedure
was successful and that the patient was discharged home on the second day post-
surgery.
This patient is the first to be enrolled in a clinical trial which will evaluate the safety,
performance, and clinical outcomes associated with OsStic™ in patients with
periarticular fractures. The study is fully funded and sponsored by Biomimetic
Innovations Ltd and represents an important step in building the clinical evidence
base for OsStic™.
Professor Peter Giannoudis, Professor at University of Leeds, Honorary Consultant
Surgeon at Leeds Teaching Hospitals and Principal Investigator of the study,
commented:
"We are pleased to have successfully completed the first case using OsStic™ as
part of this important clinical trial. Innovative technologies like this have the potential
to transform the way we approach fracture fixation, particularly in complex cases
where conventional methods may have limitations."
Paul Burke, Managing Partner of Biomimetic Innovations Ltd, added:
"This first-in-human use of OsStic™ represents a major milestone for our company
and our mission to bring meaningful solutions to orthopaedic care. We are excited to
partner with world-leading clinicians and institutions to evaluate the potential of this
technology to improve patient outcomes."
The First-in-Human implantation of OsStic™ marks a significant advancement in the
development of next-generation bone fixation technologies, designed to improve
outcomes in orthopaedic trauma surgery. OsStic™ hardens rapidly, conforms to
irregular defect geometries, and provides immediate mechanical support to the
subchondral bone, while promoting bone ingrowth and remodelling over time.
OsStic™ is part of Biomimetic Innovations Ltd’s pipeline of innovative medical
technologies which aim to enhance patient wellbeing.
About Biomimetic Innovations Ltd and PBC Biomed

Biomimetic Innovations Ltd is an affiliate of PBC Biomed, a medical device company
involved in design, development, manufacturing and commercialisation of Innovative
products. PBC Biomed, through its advanced medical service portfolio, partners with
medical device, biologic, pharmaceutical and combination product innovators to
accelerate technology through the product lifecycle stages.
PBC Biomed, an ISO 13485 certified company, is headquartered in Shannon,
Ireland, with offices in Memphis, Tennessee; Chamonix, France; London, United
Kingdom; and New South Wales, Australia. PBC Biomed has a proven track record
in developing and commercializing new technologies, bringing the N-Force
Fixation/iN3 Cement to market through its affiliate company, CelgenTek Innovations
(acquired by Zimmer Biomet in 2016), and more recently bringing ReFeel® to market
as a nerve regeneration solution, with partner company Mochida Pharmaceuticals
Ltd (Japan).
For more information, please visit www.pbcbiomed.com and
www.pbcbiomed.com/osstic/.